As the biotech and pharmaceutical industry moves into 2026, multiple forces are converging at once: emerging technologies are approaching pivotal clinical readouts, regulatory and pricing frameworks are becoming operational rather than theoretical, and geopolitical pressures are reshaping supply chains and the cost of capital.  The post-pandemic wave of speculative enthusiasm has notably cooled, according to … [Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.